nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.06.2012

Hypovitaminosis D as Predisposing Factor for Atrophic Type A Gastritis: a Case–Control Study and Review of the Literature on the Interaction of Vitamin D with the Immune System

verfasst von: Antonio Antico, Renato Tozzoli, Davide Giavarina, Elio Tonutti, Nicola Bizzaro

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

1,25-Dihydroxyvitamin D displays immunoregulatory and anti-inflammatory properties, and the cells involved in innate and adaptive immune response express the vitamin D receptor and can both produce and respond to this hormone. This article aims at describing the complex immune regulatory role of vitamin D and depicting whether a correlation exists between atrophic type A gastritis and hypovitaminosis. We studied 62 autoimmune gastritis (AIG) patients and compared them to 54 lymphocytic gastritis patients, 21 Helicobacter pylori gastritis patients and 212 healthy subjects. We also statistically analyzed vitamin D concentration in 36,384 outpatients referred to our clinical laboratories. 25-Hydroxyvitamin D levels, the measurable metabolite used to determine vitamin D status in plasma, were measured by a chemiluminescent method. Average level of 25-OHD in AIG subjects was 9.8 ± 5.6 ng/mL (95% confidence interval (CI) 8.4–11.2), 11.1 ± 8.4 (CI 7.5–14.7) in H. pylori gastritis patients, 22.2 ± 13.5 (CI 18.6–25.8) in nonspecific lymphocytic gastritis patients, 21.3 ± 12.2 (CI 19.7–22.9) in healthy subjects, and 21.8 ± 13.1 (CI 21.7–21.9) in the 36,384 outpatients. Vitamin D levels in AIG patients were significantly lower than in patients with nonspecific gastritis or in the general population, supporting the hypothesis that hypovitaminosis D might be a risk factor for the development of autoimmune diseases. The low vitamin D concentration in H. pylori gastritis patients might act as predisposing factor for a more severe Th1-type aggression to the stomach epithelium.

Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491S–499SPubMedCrossRef

Zhang R, Naughton DP (2010) Vitamin D in health and disease: current perspectives. Nutr J 9:65PubMedCrossRef

Cappelletti P, Tozzoli R (2010) Laboratory and hypercalcemia. In: Lumachi F, Basso SMM (eds) Hypercalcemia pathophysiology and treatment. Bentham Science, Sharjah, pp 45–61CrossRef

Rojas-Rivera J, De La Piedra C, Ramos A et al (2010) The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 25:2850–2865PubMedCrossRef

Hewison M, Zehnder D, Chakraverty R et al (2004) Vitamin D and barrier function: a novel role for extra-renal 1a-hydroxylase. Mol Cell Endocrinol 215:31–38PubMedCrossRef

Bises G, Kallay E, Weiland T et al (2004) 25-Hydroxyvitamin D₃-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 52:985–989PubMedCrossRef

Adorini L, Penna G, Giarratana N et al (2004) Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol 89–90:437–441PubMedCrossRef

Zehnder D, Bland R, Chana RS et al (2002) Synthesis of 1, 25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13:621–629PubMed

Eyles DW, Smith S, Kinobe R et al (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29:21–30PubMedCrossRef

10.

Segersten U, Holm PK, Bjorklund P et al (2005) 25-Hydroxyvitamin D₃ 1alpha-hydroxylase expression in breast cancer and use of non-1-hydroxylated vitamin D analogue. Breast Cancer Res 7:980–986CrossRef

11.

Townsend K, Evans KN, Campbell MJ et al (2005) Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 97:103–119PubMedCrossRef

12.

Segersten U, Correa P, Hewison M et al (2002) 25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967–2972PubMedCrossRef

13.

Evans KN, Bulmer JN, Kilby MD et al (2004) Vitamin D and placental–decidual function. J Soc Gynecol Investig 11:263–271PubMedCrossRef

14.

Ma JF, Nonn L, Campbell MJ et al (2004) Mechanisms of decreased vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol 221:67–74PubMedCrossRef

15.

Bikle DD, Chang S, Crumrine D et al (2004) 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol 122:984–992PubMedCrossRef

16.

Griffin MD, Xing N, Kumar R (2003) Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23:117–145PubMedCrossRef

17.

Norman AW, Mizwicki MT, Okamura WH (2003) Ligand structure–function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment). Recent Results Cancer Res 164:55–82PubMed

18.

Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116:2062–2072PubMedCrossRef

19.

DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80:1689–1696

20.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281PubMedCrossRef

21.

Cooke NE, Haddad JG (1989) Vitamin D binding protein (Gc-globulin). Endocr Rev 10:294–307PubMedCrossRef

22.

Dusso AS, Negrea L, Gunawardhana S et al (1991) On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687–1692PubMedCrossRef

23.

Takemoto F, Shinki T, Yokoyama K et al (2003) Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 64:414–420PubMedCrossRef

24.

Yamane T, Takeuchi K, Yamamoto Y et al (2002) Legumain from bovine kidney: its purification, molecular cloning, immunohistochemical localization and degradation of annexin II and vitamin D-binding protein. Biochim Biophys Acta 1596:108–120PubMedCrossRef

25.

Adams JS, Chen H, Chun RF et al (2003) Novel regulators of vitamin D action and metabolism: lessons learned at the Los Angeles zoo. J Cell Biochem 88:308–314PubMedCrossRef

26.

Nykjaer A, Dragun D, Walther D et al (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96:507–515PubMedCrossRef

27.

Liu W, Yu WR, Carling T et al (1998) Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Investig 28:100–107CrossRef

28.

Brandi L (2008) 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol—an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull 55:186–210PubMed

29.

Brenza HL, Kimmel-Jehan C, Jehan F et al (1998) Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 95:1387–1391PubMedCrossRef

30.

Tsujikawa H, Kurotaki Y, Fujimori T et al (2003) Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17:2393–2403PubMedCrossRef

31.

Dong X, Lutz W, Schroeder TM et al (2005) Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci USA 102:16007–16012PubMedCrossRef

32.

Adorini L, Penna G (2008) Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4:404–412PubMedCrossRef

33.

Norman AW, Mizwicki MT, Norman DPG (2004) Steroid hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3:27–41PubMedCrossRef

34.

Pinette KV, Yee YK, Amegadzie BY et al (2003) Vitamin D receptor as a drug discovery target. Min Rev Med Chem 3:193–204CrossRef

35.

Brown AJ, Dusso A, Slatopolsky E (1999) Vitamin D. Am J Physiol Renal Physiol 277:F157–F175

36.

Sutton ALM, MacDonald PN (2003) Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol 17:777–791PubMedCrossRef

37.

Strugnell SA, Deluca HF (1997) The vitamin D receptor—structure and transcriptional activation. Proc Soc Exp Biol Med 215:223–228PubMed

38.

Kliewer SA, Umesono K, Mangelsdorf DJ et al (1992) Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446–449PubMedCrossRef

39.

Cheskis B, Freedman LP (1994) Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol Cell Biol 14:3329–3338PubMed

40.

Dusso AS, Brown AJ (2009) Vitamin D: molecular biology and gene regulation. In: Singh AJ, Williams GH (eds) Textbook of nephro-endocrinology. Elsevier, San Diego, pp 69–93CrossRef

41.

Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662–687PubMedCrossRef

42.

Oñate SA, Tsai SY, Tsai MJ et al (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357PubMedCrossRef

43.

Chen HW, Lin RJ, Schiltz RL et al (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580PubMedCrossRef

44.

Rachez C, Suldan Z, Ward J et al (1998) A novel protein complex that interacts with the vitamin D₃ receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12:1787–1800PubMedCrossRef

45.

Chiba N, Suldan Z, Freedman LP et al (2000) Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase II holoenzyme. J Biol Chem 275:10719–10722PubMedCrossRef

46.

Carvallo L, Henríquez B, Paredes R et al (2008) 1alpha, 25-Dihydroxy vitamin D3-enhanced expression of the osteocalcin gene involves increased promoter occupancy of basal transcription regulators and gradual recruitment of the 1alpha, 25-dihydroxy vitamin D3 receptor-SRC-1 coactivator complex. J Cell Physiol 214:740–749PubMedCrossRef

47.

Baudino TA, Kraichely DM, Jefcoat SC Jr et al (1998) Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 273:16434–16441PubMedCrossRef

48.

Zhang C, Dowd DR, Staal A et al (2003) Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J Biol Chem 278:35325–35336PubMedCrossRef

49.

Dunlop TW, Väisänen S, Frank C et al (2004) The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha, 25(OH)2D3 targets. J Steroid Biochem Mol Biol 89–90:257–260PubMedCrossRef

50.

Adorini L, Penna G (2009) Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 70:345–352PubMedCrossRef

51.

Cutolo M (2009) Vitamin D and autoimmune rheumatic diseases. Rheumatology 48:210–212PubMedCrossRef

52.

van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101PubMedCrossRef

53.

Liu PT, Stenger S, Li H et al (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773PubMedCrossRef

54.

Wang TT, Nestel FP, Bourdeau V et al (2004) Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173:2909–2912PubMed

55.

Schauber J, Dorschner RA, Coda AB et al (2007) Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117:803–811PubMedCrossRef

56.

Sigmundsdottir H, Pan J, Debes GF et al (2007) DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8:285–293PubMedCrossRef

57.

Chen S, Sims GP, Chen XX et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMed

58.

Mattner F, Smiroldo S, Galbiati F et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol 30:498–508PubMedCrossRef

59.

Cippitelli M, Santoni A (1998) Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28:3017–3030PubMedCrossRef

60.

Penna G, Amuchastegui S, Cossetti C et al (2006) Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 177:8504–8511PubMed

61.

Penna G, Amuchastegui S, Giarratana N et al (2007) 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178:145–153PubMed

62.

Adorini L, Giarratana N, Penna G (2004) Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 16:127–134PubMedCrossRef

63.

Penna G, Adorini L (2000) 1 alpha, 25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411PubMed

64.

Penna G, Roncari A, Amuchastegui S et al (2005) Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4 + Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 106:3490–3497PubMedCrossRef

65.

Hewison M, Freeman L, Hughes SV et al (2003) Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 170:5382–5390PubMed

66.

Adorini L (2005) Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 233:115–124PubMedCrossRef

67.

Griffin MD, Dong X, Kumar R (2007) Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch Biochem Biophys 460:218–226PubMedCrossRef

68.

Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275–306PubMedCrossRef

69.

Lemire JM, Archer DC, Beck L et al (1995) Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 125:1704S–1708SPubMed

70.

D’Ambrosio D, Cippitelli M, Cocciolo MG et al (1998) Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101:252–262PubMedCrossRef

71.

Boonstra A, Barrat FJ, Crain C et al (2001) 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974–4980PubMed

72.

Mahon BD, Wittke A, Weaver V et al (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89:922–932PubMedCrossRef

73.

Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13:139–145PubMedCrossRef

74.

Gregori S, Giarratana N, Smiroldo S et al (2002) A 1alpha, 25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367–1374PubMedCrossRef

75.

Gregori S, Casorati M, Amuchastegui S et al (2001) Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167:1945–1953PubMed

76.

Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef

77.

Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95:471–478PubMedCrossRef

78.

Antico A (2008) Autoimmune gastritis. It J Lab Med 4:125–133

79.

De Block CE, De Leeuw IH, Van Gaal LF (2008) Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 93:363–371PubMedCrossRef

80.

Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373PubMedCrossRef

81.

Kairisto V, Poola A (1995) Software for illustrative presentation of basic clinical characteristics of laboratory tests—GraphROC for Windows. Scand J Clin Lab Invest 222:43–60CrossRef

82.

Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080–1086

Titel: Hypovitaminosis D as Predisposing Factor for Atrophic Type A Gastritis: a Case–Control Study and Review of the Literature on the Interaction of Vitamin D with the Immune System
verfasst von: Antonio Antico
Renato Tozzoli
Davide Giavarina
Elio Tonutti
Nicola Bizzaro
Publikationsdatum: 01.06.2012
Verlag: Humana Press Inc
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 3/2012
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-011-8255-1

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Hypovitaminosis D as Predisposing Factor for Atrophic Type A Gastritis: a Case–Control Study and Review of the Literature on the Interaction of Vitamin D with the Immune System

Abstract

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Cutting Edge Issues in Autoimmune Gastritis

Cutting-Edge Issues in Celiac Disease and in Gluten Intolerance

Cutting-Edge Issues in Primary Biliary Cirrhosis

The Clinical Significance of 25OH-Vitamin D Status in Celiac Disease

A Contemporary Review of Seafood Allergy

Cutting Edge Issues in Autoimmune Hepatitis

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO